Skip to main content

New Aspirin Guide Mobile app helping clinicians and patients... both

New Aspirin-Guide mobile app helps clinicians and patients make informed decisions about aspirin use

Posted in: Device / Technology News | Medical Research News | Medical Condition News | Pharmaceutical News

Published on June 21, 2016 at 12:15 PM

Low dose aspirin is recommended by clinicians as a preventive measure for patients who have already had a heart attack or stroke, but the risk of taking low-dose aspirin to prevent or delay a first heart attack or stroke is less clear, as the benefit for reducing the risk of cardiovascular disease (CVD) must be balanced with the increased risk of gastrointestinal or other bleeding. To help clinicians and patients make informed decisions about aspirin use, researchers at Brigham and Women's Hospital have developed a new, free, mobile app, "Aspirin-Guide" that calculates both the CVD risk score and the bleeding risk score for the individual patient, and helps clinicians decide which patients are appropriate candidates for the use of low-dose aspirin (75 to 81 mg daily).

"We developed the Aspirin-Guide app because we realized that weighing the risks and benefits of aspirin for individuals who have not had a heart attack or stroke is a complex process. The new mobile app enables individualized benefit to risk assessment in a matter of seconds while the patient is with the physician," said Samia Mora, MD, cardiologist at BWH.

In a commentary published in JAMA in the June 20 issue, and a review in JAMA Internal Medicine published on the same day, co-authors Mora, and JoAnn Manson, MD, cardiovascular epidemiologist and Chief of Preventive Medicine at BWH, review the evidence behind the use of aspirin to delay or prevent a first heart attack of stroke, and give examples of how the mobile app can help patients and clinicians including:

•calculates a 10-year cardiovascular disease risk score (heart disease and stroke) for the patient
•calculates a bleeding risk score based on the patient's individual risk factors
•uses evidence from the literature, together with the above scores, to compare the number needed to treat vs. the number needed to harm
•helps clinicians to implement current clinical guidelines for low-dose aspirin in primary prevention
•provides the ability to email a summary of the decision-making process to the patient and/or to the clinician for the patient's record.

"Aspirin-Guide is a user-friendly clinical decision support tool, that will facilitate informed and personalized decision-making about the use of aspirin in primary prevention of CVD. Patients should discuss the pros and cons of aspirin treatment with their healthcare provider," Manson said.

Source: Brigham and Women’s Hospital

Comments

Post a Comment

Popular posts from this blog

Artificial pancreas ... an option

Coming Soon: 'Artificial Pancreas' Options for Diabetes Miriam E Tucker June 20, 2016   NEW ORLEANS — Nearly closed-loop systems (also referred to as an "artificial pancreas") for improving glycemic control and minimizing hypoglycemia in type 1 diabetes are advancing rapidly, including iterations that deliver insulin alone, insulin with glucagon, or glucagon alone. Findings for several of the products in development demonstrating improvements in glycemic control and reductions in hypoglycemia were presented here at the  American Diabetes Association (ADA) 2016 Scientific Sessions . "Some people may do well on insulin only, while others may need glucagon," Vincent Crabtree, PhD, director of the artificial pancreas program at JDRF, in New York, told  Medscape Medical News , adding, "JDRF would like people to have choice, and we'd like all to be covered [by payers]." The insulin-only hybrid closed-loop 670G system (Medtronic MiniMed) is the...
Post a Comment
Read more
Liver Stem Cells Discovered in Mice Share on email Share on facebook Share on twitter Scientists successfully identified and grew a renewable population of liver stem cells for the first time, a new study reported. Tissues derived from these stem cells slightly boosted liver function when implanted into mice with a liver disorder. The findings could eventually lead to approaches that help rejuvenate damaged livers in people. A single cell was coaxed to mature into liver cells that produce common liver proteins (green and red).  Image courtesy of Huch et al.,  Nature . The liver is a large, versatile organ that has many jobs, including cleansing blood and digesting food. The liver also has a unique ability to quickly regenerate and regain its original size if partially removed by surgery. Scientists have long known that stem cells that have the potential to create more liver cells must exist in the adult liver. But until now, no one had found a way to detect a...
Post a Comment
Read more

Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic Retinopathy

Although vascular endothelial growth factor (VEGF) is a primary mediator of retinal angiogenesis, VEGF inhibition alone is insufficient to prevent retinal neovascularization. Hence, it is postulated that there are other potent ischemia-induced angiogenic factors. Erythropoietin possesses angiogenic activity, but its potential role in ocular angiogenesis is not established. METHODS We measured both erythropoietin and VEGF levels in the vitreous fluid of 144 patients with the use of radioimmunoassay and enzyme-linked immunosorbent assay. Vitreous proliferative potential was measured according to the growth of retinal endothelial cells in vitro and with soluble erythropoietin receptor. In addition, a murine model of ischemia-induced retinal neovascularization was used to evaluate erythropoietin expression and regulation in vivo. RESULTS The median vitreous erythropoietin level in 73 patients with proliferative diabetic retinopathy was significantly higher than that in 71 patients with...
Post a Comment
Read more